Concepedia

Martina Schmittnaegel

MS

7

Publications

271

Citations

7

H-Index

2015

Active since

Affiliations

Roche Pharma AG (Germany)(Current)

Roche (Switzerland)

École Polytechnique Fédérale de Lausanne

Martina Schmittnaegel is an author at Roche Pharma AG (Germany) specializing in tumor immunity, autoimmunity, and immunology.

ORCID

Top concepts

Publications per year

2015–2022

7

Publications

7

Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models

Amaia Martínez-Usatorre, Ece Kadioglu, Gaël Boivin et al. · Science Translational Medicine · 2021 · 96 citations · Full text

Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy

Abhishek S. Kashyap, Martina Schmittnaegel, Nicolò Rigamonti et al. · Proceedings of the National Academy of Sciences · 2019 · 86 citations · Full text

Efficacy of CD40 Agonists Is Mediated by Distinct cDC Subsets and Subverted by Suppressive Macrophages

Aleksandar Murgaski, Máté Kiss, Helena Van Damme et al. · Cancer Research · 2022 · 25 citations · Full text

, , +29

Committing Cytomegalovirus-Specific CD8 T Cells to Eliminate Tumor Cells by Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules

Martina Schmittnaegel, Victor Levitsky, Eike Hoffmann et al. · Cancer Immunology Research · 2015 · 22 citations · Full text

, , +14

A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells

Martina Schmittnaegel, Eike Hoffmann, Sabine Imhof-Jung et al. · Molecular Cancer Therapeutics · 2016 · 19 citations · Full text

, , +19

Rows per page

1–5 of 7